<DOC>
	<DOCNO>NCT02343042</DOCNO>
	<brief_summary>This study independently assess efficacy safety four combination therapy treatment patient relapsed/refractory multiple myeloma ( RR MM ) : selinexor + pomalidomide + dexamethasone ( SPd ) , selinexor + bortezomib + dexamethasone ( SVd ) , selinexor + lenalidomide+ dexamethasone ( SRd ) , selinexor + daratumumab + dexamethasone ( SDd ) . The abbreviation combination treatment revise use V ( Velcade ) bortezomib R ( Revlimid ) lenalidomide .</brief_summary>
	<brief_title>Selinexor Backbone Treatments Multiple Myeloma Patients</brief_title>
	<detailed_description>Multi-center , open-label , randomize ( dose schedule ) clinical study dose escalation ( Phase 1 ) expansion ( Phase 2 ) stage independently assess maximum tolerate dose ( MTD , ) efficacy , safety selinexor + pomalidomide + dexamethasone ( SPd ) , selinexor + bortezomib + dexamethasone ( SVd ) , selinexor + lenalidomide + dexamethasone ( SRd ) , selinexor + daratumumab + dexamethasone ( SDd ) patient relapsed/refractory multiple myeloma ( RR MM ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Histologically confirm diagnosis , measurable disease evidence disease progression MM , describe . 2 . Symptomatic MM , base IMWG guideline . Patients must measurable disease define least one following : Serum Mprotein ≥ 0.5 g/dL serum electrophoresis ( SPEP ) , IgA myeloma , quantitative IgA Urinary Mprotein excretion least 200 mg/24 hour Serum FLC ≥ 100 mg/L , provide FLC ratio abnormal If serum protein electrophoresis felt unreliable routine Mprotein measurement , quantitative Ig level nephelometry turbidometry acceptable . 3 . Any nonhematological toxicity ( except peripheral neuropathy describe exclusion criterion # 22 ) patient experience treatment previous clinical study must resolve ≤ Grade 2 Cycle 1 Day 1 . 4 . Adequate hepatic function within 21 day prior C1 D1 : 5 . Adequate renal function within 21 day prior C1 D1 : 6 . Adequate hematopoietic function within 21 day prior C1 D1 : 7 . SPd ( Arm 1 ) Only : Relapsed refractory MM : Documented evidence PD achieve least SD ≥ 1 cycle previous MM regimen ( i.e. , relapse MM ) ≤ 25 % response ( i.e. , patient never achieve ≥ MR ) PD within 60 day end recent MM regimen ( i.e. , refractory MM ) Previously undergone ≥ 2 cycle lenalidomide proteasome inhibitor ( separate therapeutic regimen [ maintenance ] combination ) 8 . SVd ( Arm 2 ) Only : Relapsed refractory MM : Documented evidence relapse ≥ 1 previous line therapy Not refractory bortezomib recent line therapy 9 . SRd ( Arm 3 ) Only : Patients receive ≥ 1 prior therapeutic regimen ( prior lenalidomide allow long patient refractory prior lenalidomide ) 10 . SDd ( Arm 4 Only ) : Patients receive ≥ 3 prior line therapy , include proteasome inhibitor immunomodulatory agent . 1 . Smoldering MM . 2 . MM express Mprotein FLC ( i.e. , nonsecretory MM exclude ) , quantitative immunoglobulin level use instead 3 . Documented active systemic amyloid light chain amyloidosis 4 . Active MM involve central nervous system ( CNS ) 5 . Active plasma cell leukemia 6 . Blood ( blood product ) transfusion blood growth factor within 7 day C1 D1 patient enrol Expansion Phase 7 . Radiation , chemotherapy , immunotherapy anticancer therapy ≤ 2 week prior C1 D1 , radioimmunotherapy within 6 week prior C1 D1 . Patients longterm glucocorticoid Screening , include use spinal cord compression , require washout period . Prior radiation permit treatment fracture prevent fracture well pain management 8 . Treatment investigational anticancer therapy within 3 week prior C1 D1 9 . Prior autologous stem cell transplantation &lt; 1 month , allogeneic stem cell transplantation &lt; 3 month prior C1 D1 10 . Active graft versus host disease allogeneic stem cell transplantation 11 . A life expectancy &lt; 3 month 12 . Major surgery within 4 week prior C1 D1 13 . Active , unstable cardiovascular function : 1 . Symptomatic ischemia , 2 . Uncontrolled clinicallysignificant conduction abnormality ( e.g. , patient ventricular tachycardia antiarrhythmic exclude ; patient 1st degree atrioventricular ( AV ) block asymptomatic leave anterior fascicular block/right bundle branch block ( LAFB/RBBB ) exclude ) , 3 . Congestive heart failure ( CHF ) New York Heart Association ( NYHA ) Class ≥ 3 , 4 . Myocardial infarction ( MI ) within 3 month prior C1 D1 5 . Ejection fraction ( EF ) &lt; 50 % screen 14 . Uncontrolled active hypertension 15 . Uncontrolled active infection require parenteral antibiotic , antiviral , antifungal within one week prior first dose 16 . Known active hepatitis A , B C 17 . Known HIV infection HIV seropositivity 18 . Prior history malignancy : cancer treat curative intent &gt; 5 year study enrollment without evidence recurrence allow . Cancer treat curative intent &lt; 5 year previously allow unless approve medical monitor . Exceptions include : 1 . Resected basal squamous cell carcinoma skin 2 . Carcinoma situ cervix 19 . Any active gastrointestinal dysfunction prevents patient swallow tablet , interfere absorption study treatment 20 . Currently pregnant breastfeed 21 . A serious psychiatric medical condition , opinion investigator , could interfere treatment 22 . Hypersensitivity treatment Arm patient enrol 23 . In SVd ( Arm 2 ) : Prior history neuropathy Grade &gt; 2 , Grade 2 neuropathy pain screening ( within 21 day prior C1 D1 ) 24 . Prior participation selinexor clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Selinexor</keyword>
	<keyword>KCP-330</keyword>
	<keyword>STOMP</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed/Refractory</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Pomalidomide</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Karyopharm</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Daratumumab</keyword>
</DOC>